Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and LRRK2-associated Parkinson's disease.

Brenig Therapeutics Inc. (Brenig), a pioneering neurology-focused drug development company utilizing an AI/ML-based discovery platform, today announced the closing of a $65 million Series A financing.

Brenig Therapeutics presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.

Brenig Therapeutics announces new data on its LRRK2 inhibitor drug candidate, BT-0267. The results were unveiled at the prestigious Future of Parkinson's Disease Conference.